BCP
AXDX

Blackhawk Capital Partners’s Accelerate Diagnostics AXDX Stock Holding History

Blackhawk Capital Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-45
Closed -$10K – 86
2018
Q2 		$10K Hold
45
– – 0.01% 250
2018
Q1 		$10K Hold
45
– – 0.01% 267
2017
Q4 		$12K Buy
+45
New +$10.6K 0.01% 222

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Blackhawk Capital Partners's AXDX Position: Q3 2018 in Review

Blackhawk Capital Partners sold out of Accelerate Diagnostics (AXDX) in Q3 2018, closing a stake of 45 shares — an estimated $10K sold.

Blackhawk Capital Partners first reported a position in AXDX in Q4 2017 and held it in 3 quarters. The position peaked at $12K in Q4 2017. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2018.

  • Blackhawk Capital Partners reported no remaining Accelerate Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Blackhawk Capital Partners sold 45 Accelerate Diagnostics shares in Q3 2018, an estimated $10K.
  • Blackhawk Capital Partners first reported a position in Accelerate Diagnostics in Q4 2017 and held it in 3 quarters.
  • Blackhawk Capital Partners's Accelerate Diagnostics position peaked at $12K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2018.

Based on Blackhawk Capital Partners's 13F filing for Q3 2018, filed 13 Nov 2018.